Where will tomorrow’s workforce come from? Part 2: How is the educational system responding, and how can the cell and gene therapy community at large help?

Published: 1 June 2022
Sven Kili, James Miskin, Michael Lehmicke, Qasim Rafiq, Emily Hopewell, Frank Barry, Parviz Shamlou

Welcome to a four-part series exploring a question that the entire cell and gene therapy community is struggling with at the moment: “Where will tomorrow’s workforce come from?”

The cell and gene therapy field has been advancing at a breakneck speed for the best part of a decade, fuelled by long-awaited clinical successes, commercial breakthroughs, and a related startling increase in activity from both investors and big pharma. But with this relentless pace of growth and innovation comes the fundamental challenge of developing a sufficiently large and skilled workforce to support and maintain the sector. In this second episode, we look at some of the ways in which the academic and industry communities are responding today, as well as important focus areas for future initiatives, with Sven KiliJames MiskinMichael LehmickeQasim RafiqEmily HopewellFrank Barry and Parviz Shamlou.